Archive · 10 Nov 2025
New Drug Combination Shows Promise for Aggressive Prostate Cancer
Imagine your body has tiny soldiers that sometimes grow out of control and cause sickness, like in prostate cancer.
For a man named Suresh, his cancer was very aggressive and came back even after initial treatment.
Doctors gave him a special medicine combination that works like a two-part defense.
One part stops the body from making a certain 'food' (testosterone) that the cancer soldiers love to eat.
The other part blocks any leftover 'food' from reaching the soldiers.
By taking away their food, the cancer soldiers can't grow as much and might even shrink.
This new treatment, tested in a big study called EMBARK, helped men like Suresh live longer and reduced their chance of dying from the cancer.
Early check-ups are also important to catch this sickness when it's easier to treat.
A combination therapy using leuprolide and enzalutamide has demonstrated a significant reduction in death risk for aggressive prostate cancer.
This dual-action therapy suppresses testosterone production and blocks testosterone from fueling cancer cells, effectively starving them.
The EMBARK multinational Phase 3 clinical trial showed this combination improved survival rates and lowered the death risk by over 40% compared to leuprolide alone.
Early screening, including PSA tests and digital rectal exams, is crucial for detecting prostate cancer, especially aggressive forms, when it is most treatable.
Prostate cancer incidence in India is projected to double by 2040, highlighting the importance of new and accessible treatment options.
- Who
- Patients with high-risk, aggressive prostate cancer, including Suresh Patil
- What
- A combination therapy of leuprolide and enzalutamide has shown significant effectiveness in reducing the risk of death and controlling aggressive prostate cancer.
- When
- The EMBARK trial results were published recently; Suresh Patil began combination therapy in January and saw undetectable PSA levels by six months.
- Where
- The EMBARK trial was multinational, involving patients from 17 countries; Suresh Patil is from Mumbai, India.
- Why
- The combination therapy attacks prostate cancer on two fronts by suppressing testosterone production and blocking testosterone's ability to fuel cancer cells, thus starving them.
- Patient Example
- Suresh Patil, 65-year-old retired bank manager
- Initial PSA Level
- 16 ng/mL
- Normal PSA Level
- Below 4.0 ng/mL
- Combination Therapy Drugs
- Leuprolide and Enzalutamide
- Mechanism of Action
- Suppresses testosterone production and blocks remaining testosterone from fueling cancer cells
- EMBARK Trial Finding
- Reduced death risk by over 40% in high-risk recurrent prostate cancer
- Prostate Cancer Incidence in India (Projected)
- Will double to approx. 71,000 new cases per year by 2040